Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
about
Epigenetic control of HIV-1 post integration latency: implications for therapyImpact of Chromatin on HIV ReplicationAnimal models in HIV cure researchHIV-1 functional cure: will the dream come true?Recent developments in human immunodeficiency virus-1 latency researchOngoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsBryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent mannerActivation of latent HIV using drug-loaded nanoparticlesAn in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyAn In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionEradication therapies for HIV Infection: time to begin again.Prospects for treatment of latent HIV.Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral ReservoirsEntinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells.Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineageCombinatorial latency reactivation for HIV-1 subtypes and variantsCombination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaBFinding a cure for HIV: will it ever be achievable?Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.In vitro reactivation of latent HIV-1 by cytostatic bis(thiosemicarbazonate) gold(III) complexesHistone deacetylase inhibitors and HIV latency.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIVDual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.Screening for noise in gene expression identifies drug synergiesSelective HDAC inhibition for the disruption of latent HIV-1 infection.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.Sulfonation pathway inhibitors block reactivation of latent HIV-1.Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.Apoptosis-induced activation of HIV-1 in latently infected cell lines
P2860
Q26781191-EA7F0E9E-5022-42B7-AA27-8A6A9314C1E9Q26782046-D680B7A6-FC76-4331-9378-5D84BED411A5Q26853069-B07415C8-31B5-4F43-9214-76A31DB8AB6AQ26865803-38597340-606F-44E2-8F75-092392D14F9BQ27013114-8563C6D2-FE30-436A-A98E-5F56C170669FQ28079455-C3352936-B6FF-4B52-87DC-9F473214610AQ28474468-8FA89D33-09B7-4F9D-881D-5E1B869AFCBDQ28477657-D7BD58C2-1BBC-4123-ABBB-B30811C184ACQ28538015-E4740659-7EC3-49DA-AFEA-D163DDFA34E5Q28544949-8F5EF662-D971-4206-A875-6799E8E8A227Q28546918-D290EB73-7583-443D-B20D-C0A9C8FAA6B5Q30399588-214FA328-37DE-4CE9-94E8-7F0D08768519Q30424413-E15E2CA4-A98F-4791-99AB-0E9B25243B07Q33613493-8DA3CA87-1596-4A06-84BE-AE0F950C5833Q33838633-2895F7F4-7E2E-4DE7-B87F-28DDAC9A4508Q33851786-D3462B13-3298-4A61-9591-000E524B1806Q33864438-7CA429D8-BF74-47A5-B9E3-2A0FC946D995Q33877492-3AF88ED4-DB19-45A7-9892-4CF16E122AB4Q34132738-FB9CC92C-2072-473E-AF0B-9ABA3414F147Q34145909-E37E98FC-6FD0-470A-9641-7A6BF4D4DC5DQ34180174-E07374AB-7E63-43AC-A749-A3CD3A1D0F21Q34482017-7DA39EA7-D0C6-493F-98B3-4C882EA63AD8Q34567084-7173E1EA-6D16-4A83-B45D-028920472E01Q34596417-25D0ADE4-E2EB-4CBE-AA80-FE8A26F39F49Q34694631-8BA3D03D-23FA-43C4-A423-60AED41C5233Q34816844-D1947A69-2CC4-4DD0-95DF-674DFB618091Q34869927-74895916-CC8D-4B4A-ACF8-4AE12B547922Q34988095-83DF7D72-E9B6-46A5-AD51-555A5CB52470Q35016964-F487EB82-051A-4277-A402-AF78FE22B1C5Q35035572-0E3E3548-9F29-4E91-9B75-2757489E0C49Q35168379-E704F441-A932-4EFD-B084-EF893B7A473EQ35176166-19D7041C-52F6-41EC-9AB0-5B63F2714291Q35182580-1401E967-AF1A-4BB9-AA39-F4DA32F825E1Q35227888-61D7A0BE-2E5D-4FA2-A399-A9D1A2733F9CQ35252186-4545DEB7-E0FE-4CAB-B32C-4E187F899C1EQ35252396-28EC404D-8245-401E-9DE0-CBF68F45D7A2Q35358497-B3D70FF2-4CBE-4014-833C-A669FEACD8F8Q35549754-7B1B67EC-10A0-4C4D-9D74-ED18D24A47F8Q35720063-4E257DDA-9993-4D1D-9284-694C52C07C10Q35747595-BF86D4C7-33BF-4A34-A8C8-BB63F8DC8E82
P2860
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Synergistic activation of HIV- ...... treatment of latent infection.
@ast
Synergistic activation of HIV- ...... treatment of latent infection.
@en
type
label
Synergistic activation of HIV- ...... treatment of latent infection.
@ast
Synergistic activation of HIV- ...... treatment of latent infection.
@en
prefLabel
Synergistic activation of HIV- ...... treatment of latent infection.
@ast
Synergistic activation of HIV- ...... treatment of latent infection.
@en
P2093
P2860
P50
P1433
P1476
Synergistic activation of HIV- ...... treatment of latent infection.
@en
P2093
Allan Guiguen
Aurélia Lamine
Caroline Vanhulle
Dolores Vaira
Dominique Demonte
Georges Herbein
Jacques Piette
Jean-Stéphane Gatot
Kabamba Kabeya
Miriam Calao
P2860
P356
10.1371/JOURNAL.PONE.0006093
P407
P50
P577
2009-06-30T00:00:00Z